Loss of keratinocytic RXRα combined with activated CDK4 or oncogenic nras generates UVB-induced melanomas via loss of p53 and PTEN in the tumor microenvironment

Molecular Cancer Research

Volumn 13, Issue 1, 2015, Pages 186-196

  Coleman, Daniel J ^a   Chagani, Sharmeen ^a   Hyter, Stephen ^a   Sherman, Anna M ^a,b   Löhr, Christiane V ^a   Liang, Xiaobo ^a   Ganguli Indra, Gitali ^a   Indra, Arup K ^a,c  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; BIOLOGICAL MARKER; CD11B ANTIGEN; CD31 ANTIGEN; CELL CYCLE PROTEIN 20; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLINE; FAS LIGAND; FIBROBLAST GROWTH FACTOR 2; MONOCYTE CHEMOTACTIC PROTEIN 1; OCCLUDIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACENTAL GROWTH FACTOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; RETINOID X RECEPTOR ALPHA; SCATTER FACTOR; STATHMIN; TYROSINASE RELATED PROTEIN 1; CDK4 PROTEIN, MOUSE; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PTEN PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; KERATINOCYTE; LOXP SITE; MELANOMA; MOUSE; NONHUMAN; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION INDUCED NEOPLASM; TUMOR MICROENVIRONMENT; ULTRAVIOLET B RADIATION; UPREGULATION; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MUTATION; PATHOLOGY; RADIATION RESPONSE; ULTRAVIOLET RADIATION;

MUS;

ANIMALS; CYCLIN-DEPENDENT KINASE 4; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP PHOSPHOHYDROLASES; HUMANS; KERATINOCYTES; MELANOMA; MEMBRANE PROTEINS; MICE; MUTATION; PTEN PHOSPHOHYDROLASE; RETINOID X RECEPTOR ALPHA; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 84921807484     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0164     Document Type: Article

References (51)

1. Skin Cancer Facts. American Cancer Society, 9 Mar. 2014. http://www.cancer.org/cancer/cancercauses/sunanduvexposure/skin-cancer-facts.
2. Markovic SN, Erickson LA, Rao RD, McWilliams RR, Kottschade LA, Creagan ET, et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007;82:364-80.
3. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-54.
4. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992;68:397-406.
5. Leid M, Kastner P, Chambon P. Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem Sci 1992;17:427-33.
6. Wang Z, Coleman DJ, Bajaj G, Liang X, Ganguli-Indra G, Indra AK. RXRalpha ablation in epidermal keratinocytes enhances UVR-induced DNA damage, apoptosis, and proliferation of keratinocytes and melanocytes. J Invest Dermatol 2011;131:177-87.
7. Hyter S, Bajaj G, Liang X, Barbacid M, Ganguli-Indra G, Indra AK. Loss of nuclear receptor RXRalpha in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas. Pigment Cell Melanoma Res 2010;23:635-48.
8. Li M, Chiba H, Warot X, Messaddeq N, Gerard C, Chambon P, et al. RXRalpha ablation in skin keratinocytes results in alopecia and epidermal alterations. Development 2001;128:675-88.
9. Nelson WG, Sun T-T. The 50-and 58-kdalton keratin classes as molecular markers for stratified squamous epithelia: cell culture studies. J Cell Biol 1983;97:244-51.
10. Indra AK, Castaneda E, Antal MC, Jiang M, Messaddeq N, Meng X, et al. Malignant transformation of DMBA/TPA-induced papillomas and nevi in the skin of mice selectively lacking retinoid-X-receptor alpha in epidermal keratinocytes. J Invest Dermatol 2007;127:1250-60.
11. Hyter S, Coleman DJ, Ganguli-Indra G, Merrill GF, Ma S, Yanagisawa M, et al. Endothelin-1 is a transcriptional target of p53 in epidermal keratinocytes and regulates ultraviolet-induced melanocyte homeostasis. Pigment Cell Melanoma Res 2013;26:247-58.
12. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res 2013;19:5320-8.
13. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012;18:1503-10.
14. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 1999;22:44-52.
15. Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 2005;65:4005-11.
16. Noonan FP, Recio JA, Takayama H, Duray P, Anver MR, Rush WL, et al. Neonatal sunburn and melanoma in mice. Nature 2001;413:271-2.
17. Newkirk KM, Parent AE, Fossey SL, Choi C, Chandler HL, Rajala-Schultz PJ, et al. Snai2 expression enhances ultraviolet radiation-induced skin carcinogenesis. Am J Pathol 2007;171:1629-39.
18. Liang X, Bhattacharya S, Bajaj G, Guha G, Wang Z, Jang HS, et al. Delayed cutaneous wound healing and aberrant expression of hair follicle stem cell markers in mice selectively lacking Ctip2 in epidermis. PLoS ONE 2012;7:e29999.
19. Kobayashi T, Urabe K, Winder A, Jimenez-Cervantes C, Imokawa G, Brewington T, et al. Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. EMBO J 1994;13:5818-25.
20. Yamazaki F, Okamoto H, Matsumura Y, Tanaka K, Kunisada T, Horio T. Development of a new mouse model (xeroderma pigmentosum a-deficient, stem cell factor-transgenic) of ultraviolet B-induced melanoma. J Invest Dermatol 2005;125:521-5.
21. Wang D, Stockard CR, Harkins L, Lott P, Salih C, Yuan K, et al. Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem 2008;83:179-89.
22. Dutertre S, Cazales M, Quaranta M, Froment C, Trabut V, Dozier C, et al. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. J Cell Sci 2004;117:2523-31.
23. Fang G, Yu H, Kirschner MW. The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev 1998;12:1871-83.
24. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
25. Sbodio JI, Lodish HF, Chi NW. Tankyrase-2 oligomerizes with tankyrase-1 and binds to both TRF1 (telomere-repeat-binding factor 1) and IRAP (insulin-responsive aminopeptidase). Biochem J 2002;361:451-9.
26. Kang H-W, Wang F, Wei Q, Zhao Y-F, Liu M, Li X, et al. miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. FEBS Lett 2012;586:897-904.
27. Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, Hecht JL, et al. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol 2011;123:5-12.
28. Ren JG, Jie C, Talbot C. How PEDF prevents angiogenesis: a hypothesized pathway. Med Hypotheses 2005;64:74-8.
29. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998;141:1659-73.
30. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83.
31. Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008;27:6958-69.
32. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007;4:1669-79.
33. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002;297:1352-4.
34. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
35. Xue Y, Gibbons R, Yan Z, Yang D, McDowell TL, Sechi S, et al. The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc Natl Acad Sci U S A 2003;100:10635-40.
36. Gao Y, Ferguson DO, Xie W, Manis JP, Sekiguchi J, Frank KM, et al. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 2000;404:897-900.
37. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 2002;43:1997-2006.
38. Zaidi MR, Davis S, Noonan FP, Graff-Cherry C, Hawley TS, Walker RL, et al. Interferon-gamma links ultraviolet radiation to melanomagenesis in mice. Nature 2011;469:548-53.
39. Conway SJ. Novel expression of the goosecoid transcription factor in the embryonic mouse heart. Mech Dev 1999;81:187-91.
40. Christoffels VM, Hoogaars WM, Tessari A, Clout DE, Moorman AF, Campione M. T-box transcription factor Tbx2 represses differentiation and formation of the cardiac chambers. Dev Dyn 2004;229:763-70.
41. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 2001;21:2144-53.
42. Alla V, Engelmann D, Niemetz A, Pahnke J, Schmidt A, Kunz M, et al. E2F1 in melanoma progression and metastasis. J Natl Cancer Inst 2010;102:127-33.
43. Oba J, Nakahara T, Abe T, Hagihara A, Moroi Y, Furue M. Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value. J Dermatol Sci 2011;62:116-23.
44. Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, et al. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res 2007;67:1502-12.
45. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001;10:699-703.
46. Verhaegen M, Checinska A, Riblett MB, Wang S, Soengas MS. E2F1-dependent oncogenic addiction of melanoma cells to MDM2. Oncogene 2012;31:828-41.
47. Dovey M, White RM, Zon LI. Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish. Zebrafish 2009;6:397-404.
48. Muthusamy V, Hobbs C, Nogueira C, Cordon-Cardo C, McKee PH, Chin L, et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 2006;45:447-54.
49. Yang G, Rajadurai A, Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation inmelanoma. J Invest Dermatol 2005;125:1242-51.
50. Ramirez JA, Guitart J, Rao MS, Diaz LK. Cyclin D1 expression in melanocytic lesions of the skin. Ann Diagn Pathol 2005;9:185-8.
51. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003;63:2881-90.